Cargando…
Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators
Engineered CRISPR/Cas9-based transcriptional activators can potently and specifically activate endogenous fate-determining genes to direct differentiation of pluripotent stem cells. Here, we demonstrate that endogenous activation of the PAX7 transcription factor results in stable epigenetic remodeli...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221109/ https://www.ncbi.nlm.nih.gov/pubmed/32330446 http://dx.doi.org/10.1016/j.stemcr.2020.03.026 |
_version_ | 1783533300144406528 |
---|---|
author | Kwon, Jennifer B. Vankara, Ashish Ettyreddy, Adarsh R. Bohning, Joel D. Gersbach, Charles A. |
author_facet | Kwon, Jennifer B. Vankara, Ashish Ettyreddy, Adarsh R. Bohning, Joel D. Gersbach, Charles A. |
author_sort | Kwon, Jennifer B. |
collection | PubMed |
description | Engineered CRISPR/Cas9-based transcriptional activators can potently and specifically activate endogenous fate-determining genes to direct differentiation of pluripotent stem cells. Here, we demonstrate that endogenous activation of the PAX7 transcription factor results in stable epigenetic remodeling and differentiates human pluripotent stem cells into skeletal myogenic progenitor cells. Compared with exogenous overexpression of PAX7 cDNA, we find that endogenous activation results in the generation of more proliferative myogenic progenitors that can maintain PAX7 expression over multiple passages in serum-free conditions while preserving the capacity for terminal myogenic differentiation. Transplantation of human myogenic progenitors derived from endogenous activation of PAX7 into immunodeficient mice resulted in a greater number of human dystrophin(+) myofibers compared with exogenous PAX7 overexpression. RNA-sequencing analysis also revealed transcriptome-wide differences between myogenic progenitors generated via CRISPR-based endogenous activation of PAX7 and exogenous PAX7 cDNA overexpression. These studies demonstrate the utility of CRISPR/Cas9-based transcriptional activators for controlling cell-fate decisions. |
format | Online Article Text |
id | pubmed-7221109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72211092020-05-15 Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators Kwon, Jennifer B. Vankara, Ashish Ettyreddy, Adarsh R. Bohning, Joel D. Gersbach, Charles A. Stem Cell Reports Article Engineered CRISPR/Cas9-based transcriptional activators can potently and specifically activate endogenous fate-determining genes to direct differentiation of pluripotent stem cells. Here, we demonstrate that endogenous activation of the PAX7 transcription factor results in stable epigenetic remodeling and differentiates human pluripotent stem cells into skeletal myogenic progenitor cells. Compared with exogenous overexpression of PAX7 cDNA, we find that endogenous activation results in the generation of more proliferative myogenic progenitors that can maintain PAX7 expression over multiple passages in serum-free conditions while preserving the capacity for terminal myogenic differentiation. Transplantation of human myogenic progenitors derived from endogenous activation of PAX7 into immunodeficient mice resulted in a greater number of human dystrophin(+) myofibers compared with exogenous PAX7 overexpression. RNA-sequencing analysis also revealed transcriptome-wide differences between myogenic progenitors generated via CRISPR-based endogenous activation of PAX7 and exogenous PAX7 cDNA overexpression. These studies demonstrate the utility of CRISPR/Cas9-based transcriptional activators for controlling cell-fate decisions. Elsevier 2020-04-23 /pmc/articles/PMC7221109/ /pubmed/32330446 http://dx.doi.org/10.1016/j.stemcr.2020.03.026 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kwon, Jennifer B. Vankara, Ashish Ettyreddy, Adarsh R. Bohning, Joel D. Gersbach, Charles A. Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators |
title | Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators |
title_full | Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators |
title_fullStr | Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators |
title_full_unstemmed | Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators |
title_short | Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators |
title_sort | myogenic progenitor cell lineage specification by crispr/cas9-based transcriptional activators |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221109/ https://www.ncbi.nlm.nih.gov/pubmed/32330446 http://dx.doi.org/10.1016/j.stemcr.2020.03.026 |
work_keys_str_mv | AT kwonjenniferb myogenicprogenitorcelllineagespecificationbycrisprcas9basedtranscriptionalactivators AT vankaraashish myogenicprogenitorcelllineagespecificationbycrisprcas9basedtranscriptionalactivators AT ettyreddyadarshr myogenicprogenitorcelllineagespecificationbycrisprcas9basedtranscriptionalactivators AT bohningjoeld myogenicprogenitorcelllineagespecificationbycrisprcas9basedtranscriptionalactivators AT gersbachcharlesa myogenicprogenitorcelllineagespecificationbycrisprcas9basedtranscriptionalactivators |